Geron Announced Publication In The Lancet Of Results From IMerge Phase 3 Trial Of Imetelstat Versus Placebo In Patients With Lower-risk Myelodysplastic Syndromes Relapsed/Refractory Or Ineligible For Erythropoiesis-stimulating Agents
Portfolio Pulse from Benzinga Newsdesk
Geron Corporation announced the publication of results from the IMerge Phase 3 trial of Imetelstat versus placebo in The Lancet. The trial focused on patients with lower-risk Myelodysplastic Syndromes who are relapsed/refractory or ineligible for erythropoiesis-stimulating agents.
December 04, 2023 | 10:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Geron Corporation's publication of positive Phase 3 trial results for Imetelstat could lead to increased investor confidence and potential revenue growth if the drug gains regulatory approval.
The publication of positive Phase 3 trial results in a prestigious journal like The Lancet is a significant milestone for Geron Corporation. It suggests that Imetelstat has a favorable efficacy and safety profile, which could lead to regulatory approval and commercialization. This news is likely to be viewed positively by investors, potentially leading to a short-term increase in GERN's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100